Nkarta, Inc.
NKTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 74.2% and free cash flow fell 29.2%, each against the same quarter a year earlier.
Follow NKTX
Nkarta, Inc. (NKTX) Beneish M-score
Nkarta, Inc.'s Beneish M-score for fiscal 2019 cannot be worked out: days’ sales in receivables index and gross margin index cannot be worked out.
Beneish M-score, annual
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|
How fiscal 2019’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | — | — | n/a | — |
| Gross margin index | — | — | n/a | — |
| Asset quality index | 17.38 | — | 7.02 | |
| Sales growth index | 0.02 | — | 0.02 | |
| Depreciation index | 1.13 | — | 0.13 | |
| SG&A index | 112.60 | — | −19.37 | |
| Total accruals to total assets | (0.06) | — | −0.26 | |
| Leverage index | 0.11 | — | −0.04 | |
| Beneish M-score | n/a — days’ sales in receivables index and gross margin index cannot be worked out | — | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| KRRO Korro Bio, Inc. compare | −3.5× |
| CUE Cue Biopharma, Inc. compare | −0.4× |
| NKTX Nkarta, Inc. | — |
| ALXO ALX Oncology Holdings Inc. compare | — |
| AVXL Anavex Life Sciences Corp. compare | — |
| TLSA Tiziana Life Sciences Ltd compare | — |
| MOLN Molecular Partners AG Sponsored ADR compare | — |
| ANTX AN2 Therapeutics, Inc. compare | — |
| TARA Protara Therapeutics, Inc. compare | — |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI